Technological watch
Gerresheimer, SQ Innovation developing micro pump for heart failure
Gerresheimer subsidiary Sensile Medical and Swiss biopharmaceutical company SQ Innovation AG have agreed to develop and manufacture a micro pump for the treatment of edema in heart failure.
Edema is swelling caused by excess fluid trapped in body's tissues. In patients suffering from congestive heart failure, one or both of heart's lower chambers lose their ability to pump blood effectively, causing blood to back up in body parts such as legs, ankles and feet, causing edema.
The partnership will aim to develop the micro pump for the European and American markets and the product will be launched after “the completion of development and obtaining market authorisation,” Gerresheimer said in a statement.
The new agreement will also see Sensile terminating a project launched last June with French medical giant Sanofi, to develop a micro pump system for the delivery of insulin to treat Type 2 diabetes.
The project, said Gerresheimer, was terminated for “strategic reasons” but did not give further details.
Based on rotary piston pump technology, Sensile’s SenseCore micro pump systems are claimed to offer “a safe and cost-efficient platform” which is highly customisable to meet the drug product’s needs.
In September last year, the company developed and launched a micro pump solution for Parkinson’s treatment.
“Our micro pump technology is highly advanced and very competitive. It can be used for a variety of treatments across medical conditions,” said Dietmar Siemssen, CEO of Gerresheimer AG, adding that the pipeline of projects for the micro pump technology was “very promising”.
Based in Olten, Switzerland, Sensile was acquired by German pharama and medical packaging firm Gerresheimer in 2018 and is specialised in developing micro pumps.
Edema is swelling caused by excess fluid trapped in body's tissues. In patients suffering from congestive heart failure, one or both of heart's lower chambers lose their ability to pump blood effectively, causing blood to back up in body parts such as legs, ankles and feet, causing edema.
The partnership will aim to develop the micro pump for the European and American markets and the product will be launched after “the completion of development and obtaining market authorisation,” Gerresheimer said in a statement.
The new agreement will also see Sensile terminating a project launched last June with French medical giant Sanofi, to develop a micro pump system for the delivery of insulin to treat Type 2 diabetes.
The project, said Gerresheimer, was terminated for “strategic reasons” but did not give further details.
Based on rotary piston pump technology, Sensile’s SenseCore micro pump systems are claimed to offer “a safe and cost-efficient platform” which is highly customisable to meet the drug product’s needs.
In September last year, the company developed and launched a micro pump solution for Parkinson’s treatment.
“Our micro pump technology is highly advanced and very competitive. It can be used for a variety of treatments across medical conditions,” said Dietmar Siemssen, CEO of Gerresheimer AG, adding that the pipeline of projects for the micro pump technology was “very promising”.
Based in Olten, Switzerland, Sensile was acquired by German pharama and medical packaging firm Gerresheimer in 2018 and is specialised in developing micro pumps.
This project has received funding from the Bio Based Industries Joint Undertaking under the European Union’s Horizon 2020 research and innovation programme under grant agreement No 837761.
